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INTRODUCTION 
 
 
 
 
 
INTRODUCTION 
 
The second half of the 20th century has witnessed a global spread of  Coronary 
Artery Disease (CAD) especially in developing countries, including India.  Major risk 
factors are sedentary life style, cigarette smoking, hypertension, high LDL cholesterol 
and diabetes mellitus. 
 
 However, there are a substantial number of cases who do not have these traits 
and habits and yet they suffer at a young age and have very advanced coronary 
atherosclerosis.  To explain this enigma, numerous newer coronary risk factors like 
hyperhomocysteinaemia, heredofamilial factors, socioeconomic factors and 
psychosocial stress have been implicated in the pathogenesis of coronary artery 
disease.   
Hyperhomocysteinemia has received increasing attention during the past 
decade and has joined smoking, dyslipidemia, hypertension and obesity as an 
independent risk factor for cardiovascular disease.  In addition, elevated 
Homocysteine levels have been implicated in a number of other clinical conditions 
including renal failure, rheumatoid arthritis, alcoholism, osteoporosis, 
neuropsychiatric disorders, diabetes mellitus and complications of diabetes. 
 
 Observations in patients with homocysteinemia led to the idea that tHcy may 
be involved in the pathogenesis of atherosclerosis. This concept prompted a large 
number of epidemiological studies that assessed the relation between moderately 
elevated tHcy levels and coronary artery disease.  
 
     1 
 Observations in approximately 80 clinical and epidemiological studies 
suggested that elevated tHcy is a risk factor for atherosclerotic vascular disease and 
for arterial and venous thromboembolism. 
 
 The aim of the present study is to evaluate the role of Homocysteine as a 
predictor of MI in young South Indian patients. 
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REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
   REVIEW OF LITERATURE 
 
 
 Ischaemia refers to lack of oxygen due to inadequate perfusion of the 
myocardium, which causes an imbalance between oxygen supply and demand. The 
most common cause of myocardial ischaemia is obstructive atherosclerotic disease of 
the epicardial coronary arteries.  
EPIDEMIOLOGY OF CORONARY ARTERY DISEASE  
Incidence in Developed Countries 
Coronary artery disease causes more deaths and disability and incurs greater 
economic costs than any other illness in the developed countries. A high fat and 
energy rich diet, smoking and a sedentary lifestyle are associated with emergence of 
coronary artery disease. In the Western World it is growing amongst the poor rather 
than the rich (who are adopting more healthful lifestyles) while primary prevention 
has delayed the disease to later life in all economic groups. Obesity, insulin resistance 
and type II Diabetes are increasing and are powerful risk factors for CAD. 
 CAD in South Asians  
While death rates of CAD have been declining over past three decades  
for the population as a whole, a disturbing trend has been noted among the persons of 
the South Asian origin. With urbanization in developing countries the prevalence of 
risk factors for CAD is increasing rapidly in these regions. 
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(a) Prevalence among immigrant South Asians2 
 The term ‘South Asians’ includes persons who originated from nations of the 
Indian subcontinent – India, Pakistan, Bangladesh, Nepal, Bhutan and Srilanka.  
 For the approximately 16 million Asian Indians living outside India, prevalence of 
risk factors including hypertension, dyslipidemia, central obesity and diabetes, is not 
only higher in this population, but is also rapidly increasing. 
 
(b) Prevalence among immigrant Indians3  
 The prevalence of CAD among immigrant Indians is about three-fold higher 
than in comparable indigenous population.  On an average, a three-fold-higher 
prevalence of CAD has been noted among Indians when compared to the respective 
native inhabitants.  CAD tends to occur earlier in life among people of Indian descent.  
Mortality attributable to CAD is substantially higher among Indian immigrants across 
all age groups and is remarkably pronounced in the young. 
 
(c) Prevalence of CAD in native Indians2  
 Prevalence of CAD among Indians living in India has also been shown to be 
high in multiple cross-sectional studies. Of the 2.78 million deaths caused by 
cardiovascular diseases, ischaemic heart disease caused 1.51 million deaths.  
Assessment of disease burden using the disability adjusted life years (DALYs) 
methodology revealed that cardiovascular diseases contributed to 30.5 million 
DALYs of which the major share was ischaemic heart disease (15.1).   
It is apparent that cardiovascular diseases especially coronary heart disease are major 
cause of death in India and absolute mortality due to coronary heart disease shall 
increase from 1.59  
4 
million/year in the year 2000 to 2.03 million in 2010 and 2.58 million by the year 
20202. 
 
 However, the prevalence of CAD among native Indians is less than among 
immigrant Indians and there’s a definite urban-rural gradient in disease prevalence.  
Overall, the prevalence estimates obtained from the studies performed in the last 
decade range between 7.6% and 12% for urban population and 3.1 to 7.4 for rural 
population3.  The rates appear to be higher in South India with highest in Kerala12. 
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Cardivascular disease mortality in different Indian states (rates/100,000)40 
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Although the large epicardial coronary arteries are capable of constriction and 
relaxation in healthy persons, they serve as conduits and are referred to as 
conductance vessels, while the intramyocardial arterioles normally exhibit changes in  
      
and are therefore referred as resistance vessels. Abnormal constriction (Prinzmetal 
angina) or failure of normal dilation of the coronary resistance vessels can cause 
ischaemia. 
 The normal coronary circulation is dominated and controlled by the heart’s 
requirement of oxygen. This need is met by the ability of the coronary vascular bed to 
vary its resistance considerably while the myocardium extracts a high and relatively 
fixed percentage of oxygen. Intramyocardial resistance vessels demonstrate an 
immense capacity for dilatation. For example, the changing oxygen need for the heart 
with exercise and emotional stress affect coronary vascular resistance and in this 
manner regulate the supply of oxygen and substrate to the myocardium. The coronary 
resistance vessels also adapt to physiological alteration in blood pressure in order to 
maintain coronary blood flow at levels appropriate to myocardial needs (auto- 
regulation) 
 By reducing the lumen of coronary arteries atherosclerosis limits its 
appropriate increase in perfusion when the demand for flow is augmented, as occurs 
during exercise or excitement. When the luminal reduction is severe, myocardial 
perfusion in the basal state is reduced. Epicardial coronary arteries are the major sites 
of atherosclerotic disease.  
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MAJOR RISK FACTORS FOR ATHEROSCLEROSIS: 
¾ Cigarette smoking 
¾ Hypertension (BP≥140/90) 
¾ Low HDL cholesterol 
¾ Diabetes mellitus 
¾ Family history of premature CAD 
o CAD in male first degree relatives <55yrs 
o CAD in female first degree relative <65yrs 
¾ Age (men≥45yrs, women≥55yrs) 
¾ Life style risk factors 
o Obesity (BMI≥30kg/m2) 
o Physical inactivity 
o Atherogenic diet 
¾ Emerging risk factors 
o Lipoprotein(a) 
o Homocysteine 
o Prothrombotic factors 
o Proinflammatory factors 
o Impaired fasting glucose 
o Subclinical atherogenesis 
These risk factors for atherosclerosis disturb the normal functions of 
vascular endothelium. These functions include local control of vascular tone, 
maintenance of anti-coagulant surface and defense against inflammatory cells.  
8 
The loss of these defences leads to inappropriate constriction, luminal 
clot formation and abnormal interaction with blood monocytes and platelets. 
The latter results in the subintimal collections of fat, smooth muscle cells, 
fibroblasts and intercellular matrix(atherosclerotic plaques) which develops at 
irregular rates in different segments of the epicardial coronary tree and lead 
eventually to segmental reduction in cross sectional area. When a stenosis 
reduces the cross sectional area by 75% full range of increase in flow to meet 
increased myocardial demand is not possible. When the luminal area is 
reduced ≥80%, blood flow at rest may be reduced and further minor decreases 
in the stenotic orifice can reduce coronary flow dramatically and cause 
myocardial ischaemia.  
 Segmental atherosclerotic narrowing of epicardial coronary arteries is 
most commonly by the formation of a plaque, which is subject to fissuring, 
erosion, haemorrhage and thrombosis. Any of these events can temporarily 
worsen the obstruction, reduce coronary blood flow and cause clinical 
manifestations of myocardial ischaemia. The location of the obstruction 
influences the quantity of  myocardium rendered ischaemic and determines the 
severity of clinical manifestations. 
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HOMOCYSTEINE14 
 
 
 Homocysteine is an aminoacid produced in the human body by the chemical 
conversion of methionine, a compound regularly consumed within the diet. When 
methionine-rich foods such as fish are eaten, the methionine is taken into the blood 
stream and into cells where a methyl group (one carbon and three hydrogen atoms) is 
removed to produce Homocysteine. 
 
 Homocysteine sits at the juncture of two critical metabolic pathways: the 
remethylation/transmethylation and trans-sulphuration pathways. Remethylation 
converts Homocysteine to methionine and requires folate and cobolamin (vitamin 
B12).  The trans-sulphuration pathway requires pyridoxine (vitamin B6) as a cofactor 
and condenses Homocysteine with serine to form glutathione and finally cysteine. 
 
 Hence, Homocysteine perform a necessary function in the body by converting 
itself to glutathione - the body’s best anti-ageing agent (and also works as detoxifier) 
and other beneficial compounds such as ATP, S-adenosyl methionine, creatinine, 
choline part of RNA & DNA messengers and epinephrine. 
 
 The main sites of metabolism are in the  kidney and  the liver and optimal  
levels of folic acid are needed to keep Homocysteine low. 
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EPIDEMIOLOGY OF HOMOCYSTEINEMIA14 
 
1. Genetic defects 
 Many enzymes or catalysts are involved in the complete metabolism of 
Homocysteine.  If any of these enzymes is defective or functions inefficiently due to a 
mutated or defective gene, the body is less able to successively process 
Homocysteine. 
 
2. Age  
 Children before puberty have low levels (about 6 µ mol/lit). During puberty, 
levels increase to a greater extent in boys than in girls. 
 
 By age 40-42, the average concentration of Homocysteine is about 11 and  
9 µmol/L in men and women respectively. 
 
 In the elderly, higher Homocysteine levels may be caused by many factors 
including physiological age-related changes. Reduced appetite may lead to inadequate 
consumption of vitamins and when combined with slower metabolism, this could lead 
to elevated Homocysteine levels. 
 
3. Pregnancy  
 During pregnancy, Homocysteine concentrations are reduced by up to 50% 
possibly due to increased metabolism and also higher plasma volume. 
11 
 
 
 
 
 
 
4. Life style factor which increase Homocysteine levels include  
a.  Diet – A low diet with deficiency of nutrients particularly B-6, B-12, and folic 
acid. 
b.  Smoking 
c.  Alcohol – high alcohol intake reduce the absorption of vitamins. 
d.  Lack of physical exercise and excessive stress. 
e.  Obesity. 
f.  Drugs such as Oral contraceptive pills, L-Dopa, Methotrexate, Nicotinic acid, 
Theophylline, etc. 
g. Renal failure, hypothyroidism, psoriasis and malignancies. 
 
THE EFFECT OF HYPERHOMOCYSTEINEMIA 
 High levels of Homocysteine have been linked to the development of a 
number of common conditions.  Homocysteine has also been shown to play a crucial 
role as a key marker for disease development determining longevity and health 
throughout a person’s life. 
 
1. Pregnancy and new borns16, 18 
 Women with high Homocysteine levels find it harder to conceive, are at risk 
from repeated early miscarriages and are over twice as likely to experience pregnancy 
complications. 
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2. The middle years  
a. Coronary Heart Disease17, 18, 19 
 
Homocysteine is believed to be a causal influence on the development of 
cardiovascular disease and the subsequent likelihood of myocardial infarction. 
Homocysteine has the ability to change cholesterol into a far more sinister version 
which attacks arterial walls.  Homocysteine also results in increased coagulability of 
blood leading to coronary artery occlusion.   
b. Stroke18 
 Like CAD, strokes are also greatly influenced by high Homocysteine levels. 
c. Diabetes18 
 People with diabetes are at risk of having high Homocysteine levels. 
d. Osteoporosis18 
 Osteoporosis, a condition where the density of bone-mass decreases leading to 
fragile, weakened bones, has been strongly linked to homocysteinuria and associated 
with high Homocysteine levels. 
 
e. Alzheimer’s  Dementia20 
 After 80 years of age, 20% of people develop dementia, the most common 
form being Alzheimer’s disease.  As Homocysteine levels increase, brain undergoes 
oxidative stress and lessens the chance of repairing damaged DNA.  Over time, 
memory loss increases as more and more cells die. 
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MEASUREMENT OF HOMOCYSTEINE – THE SCALE OF HEALTH21 
 Homocysteine is measured in micromole per litre of blood (µmol/L). 
 There is really no healthy level for Homocysteine but generally the lower, the 
better. A ‘safe zone’ is normally considered to be below 10 µmol/L. 
Normal range:  5 – 15 µmol/L. 
Hyperhomocysteinemia: 
Mild  : 15 – 20 µmol/L 
Intermediate  : 25 – 50 µmol/L 
Severe  : Above 50 µmol/L 
 
REDUCING THE RISK14  
a. A 3 µmol/L drop in Homocysteine lessens the likelihood of MI by 16%, 
strokes by 24% and deep vein thrombosis by 25%. 
b. A 5 µmol/L decrease in Homocysteine reduces the risk of death from all 
causes by 49%, death from cardiovascular disease by 50% and death from 
cancer by 26%. 
 
MANAGEMENT OF HYPERHOMOCYSTEINEMIA 
 Once elevated Homocysteine has been diagnosed, the next step is a simple 
examination of diet.  A healthy balanced diet containing at least five servings of fruits 
and vegetables a day will help to lower the Homocysteine level and keep within the 
ideal range. 
 
 Folic acid and vitamins B-6 and B-12 have been shown to have the greatest 
effect at breaking down harmful Homocysteine from within the body14. 
14 
Foods rich in folic acid include: 
a. Green leafy vegetables such as spinach, cabbage, etc. 
b. Citrus fruits particularly orange and grape fruits. 
c. Pulses such as black-eyed beans and chick peas. 
d. Whole grain cereals. 
 
 Maintaining low plasma Homocysteine is also easily achieved through vitamin 
supplementation.  Patients with elevated Homocysteine (> 14 µmol/L with no other 
risk factors, or > 11 µmol/L for patients with more than 2 risk factors) can be treated 
effectively with multivitamins containing 400 µg of folic acid supplemented with an 
additional 400 to 1000 µg of folic acid.  After 6 to 8 weeks of vitamin 
supplementation, Homocysteine should be repeated. Continued elevated 
Homocysteine should be treated with increased doses of supplemental folic acid up to 
5mg/d.15 
 
          For many people, the daily intake of 500 µg TMG (Trimethyl glycine), 800 µg 
of folic acid, 1000 µg of vitamin B12 and 250 mg of choline, 250 mg of inositol, 
30mg of zinc and 100mg of vitamin B6 will keep Homocysteine levels in the normal 
range. 
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 HOMOCYSTEINE AND CORONARY ARTERY DISEASE: 
 Homocysteine is a thiol containing amino acid derived from the metabolism of 
methionine that circulates in plasma in 3 forms : as a single free amino acid (1%), as 
Homocysteine or cysteine-Homocysteine disulfides (20% to 30%) or bound to plasma 
proteins (70% to 80%). Together, these account for the total plasma Homocysteine 
(tHcy).  Inborn errors of metabolism arising from a deficiency of Hcy-metabolizing 
enzymes result in extremely high tHcy concentrations and are associated with 
atherosclerosis and premature thrombosis. 
 
 Case-control studies have reported stronger associations than prospective 
studies in which some but not others claim that Hyperhomocysteinemia is a risk factor 
for future stroke development. 
 
 A prospective, cohort, 10-year follow-up study on plasma Homocysteine 
levels and prognosis in patients with previous premature myocardial infarction was 
done in Akershus University Hospital. A total of 247 patients (193 men and 54 
women) in stable clinical phase after premature MI were included as subjects. The 
primary end point measured was total mortality and the secondary end-point was 
cardiac death.  The third end-point was major cardiac events: a combination of cardiac 
death, MI and cardiac arrest.  A long-term increase in risk of death was observed with 
increasing tHcy, suggesting that tHcy is a predictor of cardiac death  in relatively 
young stable CHD patients.21 
 An epidemiological study on plasma Homocysteine levels and atherosclerosis 
was done in Japan by use of carotid ultrasonography. 
16 
  In 1111 cases (452 men and 659 women) aged 63 ± 10 years old, recruited from a 
population-based survey, fasting plasma total Homocysteine levels were measured 
and bilateral carotid B-mode ultrasound was performed.  It was found that for the total 
population, the mean Homocysteine level was 10.9 L/molµ .  Total Homocysteine 
levels were higher in men than in women and increased with ageing.  It was 
concluded that plasma total Homocysteine levels in Japan are similar to those reported 
in western countries. Mild Hyperhomocysteinemia is an independent factor for 
increased carotid artery wall thickness in Japan as well.22 
 
 A case-control study of plasma Homocysteine levels in South Indians with and 
without coronary artery disease was done in Hyderabad.  In the study, plasma 
Homocysteine levels were estimated in 565 subjects of whom 221 were cases and 344 
were controls. Of the 221 clinically defined cases, 112 underwent coronary 
angiography while 107 of the 344 controls had angiographically proven normal 
coronary arteries. Fluorescent polarization immunosorbent assay was used to measure 
plasma Homocysteine levels.  It was found that the mean plasma Homocysteine level 
was 18.30 ± 10.08 L/molµ  in clinically defined cases and 18.04 ± 10.69 L/molµ  in 
controls.  Similarly, in angiographically proven coronary artery disease patients, the 
mean plasma Homocysteine level was 18.49 ± 10.04 L/molµ  and in individuals with 
angiographically normal coronary arteries, it was 19.16 ± 11.38 L/molµ .  It was 
concluded that there is no statistically significant difference in plasma Homocysteine 
levels between controls and cases with coronary artery disease.23 
 
17 
A cohort follow-up study on plasma Homocysteine levels and mortality in patients 
with coronary artery disease was done in Norway. 587 patients with angiographically 
documented coronary disease were studied between February 1991 and June 1992.  
Angiogram was interpreted and stenoses of at least 50% were considered significant.  
After median follow-up of 4.6 years, overall mortality was 11.1% among men and 
10.1% among women with a strong, graded dose-response relationship to 
Homocysteine levels. It was found that patients with higher plasma Homocysteine 
levels at baseline had a higher mortality. However, Homocysteine did not correlate 
with the degree of coronary disease. Furthermore, serum lipids, which correlate with 
the extent of coronary disease, did not correlate well with mortality. Thus it was 
concluded that Homocysteine has a role in the development of thrombotic events, 
where as the role of lipids is more in the development of atherosclerosis.24 
 
 A case-control study on the role of Homocysteine and lipoprotein (a) in 
coronary artery disease was done to look at the possible role of some nontraditional 
risk factors for premature coronary artery disease and assess the presence of the 
relationship between these factors and the traditional cardiovascular risk factors. The 
study subjects (n=45) were divided into three groups comprising 15 premature CAD 
patients without traditional cardiovascular risk factors, 15 premature CAD patients 
with one or more traditional cardiovascular risk factors and 15 healthy normal control 
subjects, matched for age and sex.  Estimation of plasma Homocysteine was 
performed by enzyme-linked immunosorbent assay.  
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 Results showed a significant association between elevated Hcy and low folate levels 
and premature CAD in both patient groups.  
 
 It was concluded that Hcy and folic acid might serve as independent risk factors for 
premature CAD in patients, both with and without traditional risk  
factors.  However, Lp (a) might confer an additional coronary risk factor only in 
presence of traditional risk factors.25 
 
 A prospective, case-control study was conducted to assess the risk of incident 
ischemic stroke conferred by serum total Homocysteine among patients with  
pre-existing stable coronary artery disease.  With a nested case-control design, the 
baseline total Homocysteine concentration was measured in sera of matched case-
control pairs:  patients who developed ischemic stroke during a mean follow-up of 8.2 
years (cases) and age and sex-matched controls without subsequent cardiovascular 
events. It was found that an increase of 1 natural log unit in Homocysteine 
concentration was associated with a > 3-fold increase in relative odds of incident 
ischemic stroke.  It was concluded that serum total Homocysteine concentration is a 
strong predictor of incident ischemic stroke among patients at increased risk because 
of chronic CHD.26 
 
 A prospective, multicenter study was conducted to examine changes in 
Homocysteine in the acute phase after an incident stroke.  Blood samples were 
collected at days 1, 3 5, 7 and between 10 and 14 days after the stroke.  Seventy six 
participants (51 men) were enrolled. Mean age was 65.6 years, and subjects had at 
least two Homocysteine measurements.   
19 
The estimated mean Homocysteine level at baseline was 11.3± 0.5 L/molµ  which 
increased consistently to a mean of 12.0 ± 0.05, 12.4± 0.5, 13.3± 0.5 and 13.7± 0.7 
L/molµ  at days 3, 5, 7 and 10 to 14 respectively. The magnitude of the change in 
Homocysteine was not affected by age, sex, smoking status, and alcohol use, history 
of hypertension or diabetes or Rankin Scale Score.  Thus these data suggest that 
clinical interpretation of Homocysteine after stroke and the eligibility for clinical 
trials assessing treatment for elevated Homocysteine levels require an adjustment in 
time since stroke to properly interpret the observed Homocysteine levels.27 
 
 The Zutphen Elderly study was a longitudinal population-based cohort, 10-
year follow-up study that investigated the association of serum Homocysteine and risk 
of coronary artery disease and cerebrovascular disease in Elderly men. Serum 
Homocysteine levels in 878 elderly men were investigated (mean age at baseline, 71.5 
years; range, 64 to 84 years). After adjustment for other major risk factors, high 
Homocysteine levels at baseline were associated with an increased baseline 
prevalence of myocardial infarction and with a marginally significant increase in the 
risk of coronary artery disease but not with an increased risk of first-ever myocardial 
infarction.  Thus it was concluded that in a general population of elderly men, a high 
Homocysteine level is common and is strongly associated with the prevalence of 
coronary artery disease and cerebrovascular disease.28 
 
 The Northern Manhattan study is a population-based cohort study that 
investigated the association between Homocysteine and the risk of ischemic stroke, 
myocardial infarction and vascular death in a Triethnic cohort.   
20 
Baseline values of tHcy and methylmalonic acid were measured among 2939 subjects 
(mean age, 69 ± 10; 61% women, 53% Hispanics, 24% blacks and 20% whites).  Cox 
proportional models were used to calculate hazard ratios (HRs) and 95% CIs in tHcy 
categories after adjusting for age, race, education, renal insufficiency, B12 deficiency, 
and other risk factors. The adjusted HR for a tHcy level of15 µmol/L was compared 
 with < 10 µmol/L and was greatest for vascular death followed by combined.  
Vascular events (HR = 2.27; to Ischemic stroke (HR = 2.01; and nonvascular death 
(HR = 2.02; 95%).  The effect of tHcy was stronger among whites and Hispanics, but 
not a significant risk factor for blacks. Thus it was concluded total Hcy elevations 
above 15 µmol/L are an independent risk factor for ischemic stroke, where as mild 
elevations of tHcy of 10 to 15 µmol/L are less predictive.  The vascular effects of 
tHcy are greatest among whites and Hispanics and less among blacks.29 
 
 A case-control study was done in the United Kingdom on the plasma 
Homocysteine concentration in the acute and convalescent periods of 
Atherothrombotic stroke.  The fasting plasma Homocysteine concentrations of one 
hundred six patients (59 men and 47 women, mean age 57.2 (25 to 70) and 56.5 (26 to 
69 years, respectively) were measured immediately after atherothrombotic stroke and 
in the convalescent period. It was found that the Median tHcy in the acute phase of 
stroke was not significantly higher than in matched control subjects.  Median plasma 
concentrations increased significantly in the convalescent period and were then 
significantly higher than in control subjects in both men and women, (P = 0.03 and 
0.05 respectively, Mann-Whitney U test).  
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 Thus the data did not support the hypothesis that raised plasma Homocysteine 
concentrations predate atherothrombic stroke.30 
 
 
 A longitudinal, prospective study on Homocysteine and risk of recurrent 
stroke was done in Denmark to investigate whether elevated total Homocysteine 
(tHcy) measured within 24 hours of acute stroke was an independent risk factor for 
recurrent stroke and to compare levels of tHcy in groups of patients with diagnosis of 
ischemic and hemorrhagic cerebrovascular events. Fasting tHcy was measured in 
1039 stroke patients (mean age, 75 years).  It was found that serum Homocysteine 
was significantly higher in the 105 patients who experienced a stroke recurrence 
during the follow up period than in patients without recurrence.  At the index event, 
serum Homocysteine was significantly higher in 909 patients with ischemic 
cerebrovascular events than in 30 patients with intracerebral hemorrhage.  It was 
concluded that elevated tHcy is an independent risk factor for recurrent stroke.31  
 
 A cross-sectional population based study was done in Northern Greece to 
examine the association between plasma Homocysteine levels and coronary artery 
disease.  Plasma fasting tHcy levels were measured in 42 patients with 
angiographically documented CAD and compared to 42 age-and sex-, BMI-, and 
smoking habit-matched control subjects. Plasma vitamin B12, folic acid and 
lipoprotein levels and conventional risk factors for CAD were also estimated.  It was 
found that in univariate analysis, tHcy levels were higher in patients compared to 
controls.  Multivariate analysis of conventional risk factors showed that tHcy levels 
were not an independent risk factor for CAD.   
22 
However, tHcy levels were significantly higher in patients with a previous history of 
myocardial infarction  
compared to patients without such a history and to controls.  It was concluded that in 
Northern Greece, plasma tHcy levels may not be an independent risk factor for 
angiographically documented CAD patients.32 
 
 A prospective, population-based study on Hyperhomocysteinemia as a 
cardiovascular risk factor was done in Mumbai to assess Homocysteine, vitamin B12 
and folic acid concentration in resident Indian women and to study their correlation 
with traditional risk factors of coronary artery disease. The study included 137 
consecutive women who attended a health care program for women and above 40 
years of age. It was found that prevalence of Hyperhomocysteinemia was 24.2%.  No 
correlation was found between plasma Hcy and blood sugars, lipids, age, body mass 
index and menopausal status.  The CAD risk was assessed using Framingham risk 
score, and this too did not show a correlation with plasma Hcy. Hence, it was 
concluded that a large number of women from the present study had 
hyperhomocysteinemia and were deficient in vitamin B12.  A significant negative 
correlation between vitamin B12 and plasma Hcy levels was found in these older 
women.  Most Indian studies including the present one do not show a positive 
correlation between elevated Hcy levels and CAD inspite of a large percentage of 
persons showing elevated Homocysteine levels.33 
 
 A prospective study was done in India on raised serum Homocysteine levels in 
patients of coronary artery disease and the effect of vitamin B12 and folate on its 
concentration.  
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 This study included 70 cases and 70 controls presenting with acute coronary 
symptoms.  
 
It was found that mean Homocysteine levels in patients (22.81± 13.9) were 
significantly higher than the controls (7.77± 9.3).  However no statistically significant 
correlation could be reduced between Homocysteine vitamin B12 and folate.  
Cumulative analysis have indicated an increase in Homocysteine levels among 
patients with CAD with every additional risk factor.44 
 
 A prospective study on hyperhomocysteinemia and risk of ischemic stroke 
among young Asian adults was done in Singapore.  The study included 109 
consecutive young (<50 years) first-ever hospitalized ischemic stroke patients and 88 
age/gender-matched hospital-based controls during a period of 18 months.  
Prevalence of vascular risk factors was assessed; fasting Homocysteine, vitamin B12, 
and folate were assayed.  Stroke mechanisms were sub typed using TOAST study 
criteria.  It was found that mean fasting Homocysteine levels were significantly higher 
in cases (13.7µmol/L) than controls (10.8 µmol/L).  Mean vitamin B12 levels were 
significantly lower in cases than control.  Folate levels were not significantly 
different.  Mean Homocysteine levels were significantly elevated in large-artery 
strokes, but not other stroke subtypes compared with controls.  It was concluded that 
hyperhomocysteinemia is an independent risk factor for ischemic strokes in young 
Asian adults.45 
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HOMOCYSTEINE AND OTHER DISEASE  
 Elevated Homocysteine levels have been implicated in a number of clinical 
conditions other than cardiovascular diseases such as diabetes mellitus, renal failure, 
neuropsychiatric disorders, rheumatoid arthritis and osteoporosis. 
 
 A cross-sectional study on distribution of serum total Homocysteine and its 
association with diabetes and cardiovascular risk factors of the insulin resistance 
syndrome in Mexican American men was done in USA. Analysis were restricted to 
Mexican American men aged 40-74  years with data on glycated hemoglobin (%), 
body mass index (BMI), body fat distribution HDL cholesterol, fasting serum insulin, 
serum TG and fasting serum tHcy concentrations. It was found that log serum tHcy 
was not associated with prevalence of diagnosed diabetes mellitus or glycated 
hemoglobin percent or other risk factors other than age.  Log serum tHcy 
concentration showed borderline significant (P = 0.049) positive association with 
fasting serum insulin concentration independent of age and BMI  only in men aged 
60-74.  Thus it was found that no consistent association of tHcy with diabetes 
prevalence or variables of the insulin resistance syndrome were found in Mexican 
American men aged 40-74 years.34 
 
 A case-control study on plasma Homocysteine levels in obese and non-obese 
subjects with or without hypertension and its relationship with oxidative stress and 
copper was done in Turkey.  
25 
 Non-obese normotensive subjects (n: 25), non-obese hypertensive subjects (n: 25), 
obese normotensive subjects (n: 35), and obese hypertensive subjects (n: 45) 
participated in the study.  Plasma tHcy were determined by an enzyme immunoassay 
method.  Plasma lipid peroxidation levels were measured by spectrophotometric 
methods. Plasma levels of copper and insulin were measured by atomic absorption 
spectrophotometer and electrochemiluminescence method respectively.  It was found 
that plasma tHcy; copper and insulin levels did not differ in non-obese normotensives.  
Plasma lipid levels were significantly increased in non-obese hypertensives when 
compared to non-obese normotensives. Plasma tHcy, lipids, copper and fasting insulin 
levels were significantly higher in obese normotensives and hypertensives than in 
nonobese normotensives and hypertensives respectively.  There was a significant 
difference in plasma tHcy, lipid peroxide and copper levels between obese subjects 
with or without hypertension.  Thus it was concluded that in the presence of other 
traditional risk factors, Hcy may have a permissive role in the endothelial damage 
even within the normal range and this role may be related to free radical generating 
systems. Therefore, modest elevation of plasma Hcy may causally be involved in the 
pathogenesis of atherosclerosisticcardiovascular disease.35 
 A prospective study on increasing production of Homocysteine and neopterin 
and degradation of tryptophan with older age was done in Austria.  Serum 
concentrations of neopterin, Homocysteine, tryptophan (trp) and kynurenine (kyn) 
and of vitamins folate and B12 were measured in 43 healthy individuals (21 females, 
22 males) aged 34-93 years.  Comparing three age groups of similar size (34-60, 61-
71 and 72-93 years), neopterin and Homocysteine concentrations as well as kyn/trp 
ratio were found to increase with older age. 
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 Folate concentrations were lower in the middle aged group and vitamin B12 
concentration did not differ between groups.  It was concluded that the strong 
association between Homocysteine and neopterin concentrations and kyn/try implies 
that immune activation is related to the development of moderate 
hyperhomocysteinemia in the elderly.36 
 
HOMOCYSTEINE AND FOLIC ACID IN VASCULAR DISEASE 
 Lower Homocysteine levels are associated with lower rates of coronary artery 
disease and stroke.  Folic acid and vitamin B6 and B12 lower Homocysteine levels. 
 
 An analytical, case-control study was done in Iran on Homocysteine, Vitamin 
B12 and folate levels in premature coronary artery disease.  The aim of the study was 
to assess folate and vitamin B12 deficiency in the development of premature CAD.  
The study included 294 individuals less than 45 years (225 males and 69 females). It 
was found that the level of Homocysteine measured in the plasma of the male 
participants was significantly high.  However there was no significant difference in 
Homocysteine levels of females.  Based on the mean plasma level of folic acid it was 
found that 10.7% of the study group had folate and vitamin B12 deficiency. It was 
concluded that hyperhomocysteinemia is an independent risk factor for CAD in young 
patients especially in men and Vitamin B12 deficiency is a preventable cause of 
hyperhomocysteinemia.37 
 
 A randomized, double-blind, placebo-controlled trial was done on 
Homocysteine lowering with folic acid and B vitamins in Hamilton to assess whether 
vitamin supplementation reduced the risk of major cardiovascular events in patients 
with vascular disease.  
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 5522 patients 55 years of age or older who had vascular disease or diabetes were 
randomly assigned to daily treatment either with the combination of 2.5 mg of folic 
acid, 50 mg of vitamin B6 and 1 mg of vitamin B12 or with placebo for an average of 
five years.  The primary outcome was a composite death from cardiovascular equal 
MI and stroke. It was found that mean plasma Homocysteine levels decreased by 2.4 
µmol/L in the active treatment group and increased by 0.8 µmol/L per liter in the 
placebo group. Primary outcome events occurred in 519 patients assigned to active 
therapy and 547 assigned to placebo.  As compared with placebo, active treatment did 
not significantly decrease the risk of death from cardiovascular causes and MI.  Thus 
it was concluded that supplements combining folic acid and vitamin B6 and B12 did 
not reduce the risk of major cardiovascular events in patients with vascular disease.38 
 
CORONARY ARTERY DISEASE AND PREVALENCE 
 Coronary artery disease is the number one killer in developed nations.  While 
death rates of CAD have been declining over past three decades for the population as 
a whole, a disturbing trend has been noted among the persons of South Asian origin. 
Asian Indians have considerably higher prevalence of premature coronary artery 
disease and standardized mortality rates for CAD compared with Europeans. 
  
 An epidemiological study involving two residential areas in Chennai in South 
India was done to assess the prevalence and risk factors for CAD in native urban 
South Indian population.  Of the total of 1399 eligible subjects (age 20 years), 1,262 
(90.2%) participated in the study.  
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The study subjects underwent a glucose tolerance test and were categorized as having 
normal glucose tolerance (NGT), impaired glucose tolerance (IGT) or diabetes. ECG 
was performed. CAD was diagnosed based on previous medical history.  It was found 
that the overall prevalence rate of CAD is 11.0% (age standardized, 9.0%).  The 
prevalence rates of CAD were 9.1%, 14.9% and 17% in those with NGT, IGT and 
diabetes respectively.  Prevalence increased with an increase in total cholesterol.  It 
was concluded in the study that the prevalence of CAD is rising rapidly in urban 
India.  Lifestyle changes and aggressive control of risk factors are urgently needed to 
reverse this trend.39 
 
 An epidemiological study on correlation of regional cardiovascular disease 
mortality in India with lifestyle and nutritional factors were done from the mortality 
data obtained from the Registrar General of India and life style data from national 
surveys. The main aim was to determine the significance of various nutritional factors 
and other lifestyle variables in explaining the difference in cardiovascular disease 
mortality in different Indian states.  Major differences in cardiovascular disease 
mortality rates in different Indian states were reported varying from 75-100 in   
Nagaland, Meghalaya, Himachal Pradesh and Sikkim to a high of 360-340 in Andhra 
Pradesh, Tamil Nadu, Punjab and Goa.  There was a significant positive correlation of 
cardiovascular disease mortality with prevalence of obesity and dietary consumption 
of fats, milk and its products and sugars and negative correlation with green leafy 
vegetable intake.  It was concluded that there are large disparities in cardiovascular 
disease mortality in different Indian states. This can be epidemiologically explained 
by difference in dietary consumption of fats, milk sugar and green-leafy vegetables 
and prevalence of obesity.40 
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CORONARY ARTERY DISEASE AND RISK FACTORS 
 The major conventional coronary risk factors are smoking, hypertension, 
sedentary life style, high LDL cholesterol heredofamilial factors and diabetes 
mellitus.  The newer coronary  risk factors are lipoprotein (a), psychosocial stress, etc. 
   
 A cohort, prospective study on coronary artery disease in the young; 
Heredofamilial or faulty life style or both was done in India.  The study comprised 70 
young (≤  40 years) CAD patients.  There were 56 males and 14 females, mostly 
belonging to 36-40 age groups.  More than half of the patients were from low 
socioeconomic group.  It was found that 61.42% were chronic smokers and all of 
them were males. 18.8% gave history of CAD in their first degree relatives.  
Hypertension was detected in 51.42% cases, obesity in 35.71% cases and underweight 
in 14% subjects. Hypercholesterolemia was observed in 41.66% cases.  Low HDL 
was the next most common dylipidemia. 7.14%cases were diabetic.  Most ominous 
combination was smoking, low socioeconomic status, increased waist-hip ratio 
(WHR), dyslipidemia and hypertension.  The study reported that both heredofamilial 
as well as faulty life style risk factors contribute to the development of CAD in young 
people.41 
 A case control study to assess the association of lipoprotein (a) [(Lp (a)] with 
CAD was conducted in Andhra Pradesh.  151 consecutive patients with clinical and 
angiographic evidence of CAD and 49 healthy controls were drawn for the study.  
Triglycerides, VLDL-C, total-cholesterol/high density cholesterol (HDL-C) ratio, low 
density cholesterol (LDL-C)/HDL-C ratio, and Lp (a) were found to be higher in 
patients than controls. 
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 In female sex and in those with family h/o CAD, higher total and LDL cholesterol 
levels were observed to be associated with higher Lp (a) levels.  Significant difference 
in Lp(a) levels were observed between normal coronaries Vs single and triple vessel 
disease and also between single vs double and triple vessel disease.  The findings 
suggested that a cut-off level of 25mg/dl for the determination of risk of CAD.42 
  
 A case-control study to determine the relationship between plasma lipoprotein 
(a) levels and their phenotypes in a group of South Indian patients with coronary 
artery disease was done in CMC, Vellore. A total of 104 patients with 
angiographically proven coronary artery disease were compared with 104 age and 
sex-matched controls with no risk factors.  Lipoprotein (a) levels were measured by 
ELISA method and its phenotyping was done by SDS agarose gel electrophoresis.  
Plasma lipoprotein (a) levels were significantly elevated in patients with coronary 
artery disease as compared to controls Lipoprotein (a) phenotyping showed that low-
molecular weight isoforms were found only in 19.2% of the patients with coronary 
artery disease and their plasma lipoprotein (a) levels were significantly elevated 
compared to CAD patients with higher molecular weight isoforms.  It was concluded 
that plasma lipoprotein (a) levels are significantly elevated in CAD patients and the 
commoner phenotype in a south Indian population is the larger apolipoprotein (a) in 
which the lipoprotein (a) levels are lower.43 
 A case-control study on the comparative account of serum lipids, lipoproteins 
and Apolipoprotein–B in patients of coronary artery disease was done in Punjab.  
Serum total lipids (cholesterol and triglycerides), lipoproteins (VLDL, LDL and 
HDL) and Apolipoprotein-B levels of normal healthy individuals (n=25) and coronary 
artery disease patients (n=25) were estimated.   
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The objective of the present study was to ascertain the role of apo-B in causation and 
inheritance of CAD.  It was observed that on an average serum total cholesterol and 
triglyceride more than 200mg/dl bring the individuals to a risk of CAD irrespective of 
the age.  CAD patients achieved this value at an early age (35-45 years).  Similarly 
VLDL and LDL levels were found to be raised and HDL levels were found to be 
lower in CAD patients compared to age-matched controls.  Serum apo-B levels were 
significantly raised in CAD patients and patient with positive family history of CAD.  
A positive coefficient of correlation was between serum apo-B and LDL levels 
suggesting that more the number of Apo-B particles, more will be the synthesis of 
atherogenic particles (LDL).  The study concluded that elevated apo-B levels turn out 
to be a genetic factor responsible for causative factor of coronary artery disease.7 
 
 A prospective, case-cross over study was done in Israel on negative emotions, 
anger and sudden changes in posture as independent triggers for ischemic stroke.  
200 consecutive patients hospitalized with an ischemic stroke or a transient ischemic 
attack were interviewed one to four days after stroke onset using a validated 
questionnaire.  Reported exposure to potential triggers, such as negative and positive 
emotions, anger, sudden postural changes in response to a starting event, strenuous 
physical exertion, heavy eating and sudden temperature changes during a two-hour 
period prior to stroke onset were compared with the same period during the preceding 
day and to average exposures in the previous year.  Anger and other negative 
emotions were rated on a seven-point scale and were said to be present if the score 
was 5 or higher. During 2 hours before stroke 76 patients experienced at least one of 
the study triggers. Thus the study demonstrated that apart from the conventional risk 
factors, there are factors that may trigger the premature onset of stroke and this is an 
important area of potential invention.8      32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF STUDY 
 
 
 
  
AIM OF STUDY 
 
 
The aim of the present study is  
 
¾ to estimate the plasma Homocysteine levels in young patients presenting 
with myocardial infarction 
 
¾ to assess the possible role of Homocysteine as non-traditional risk factor 
in these patients  
 
 
¾ to study the association of Homocysteine with traditional risk factors. 
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STUDY PLAN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
    STUDY PLA N 
 
 The present study was planned to estimate the plasma Homocysteine in young 
patients presenting with MI, and to associate with Homocysteine with non-traditional 
risk factor and finally to assess the role of Homocysteine as a new predictor of MI  in 
young patients with signs of myocardial infarction, admitted in the Government Rajaji 
Hospital, Madurai as outlined below : 
¾ Selection of patients based on inclusion criteria. 
¾ Study of demographic and disease presenting characteristics and correlation 
with MI. 
¾ Collect patient family history and family medication history and to associate 
with the diagnosed indications. 
¾ Estimation of Homocysteine levels in MI patients and compare it with healthy 
subjects. 
¾ To study the association of Homocysteine and disease. 
¾ To explore the possible influence of Homocysteine on traditional risk factors. 
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MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
  
 
 
   MATERIALS AND METHODS 
  
Setting  
 Department of Medicine and Department of Cardiology, Government Rajaji 
Hospital, Madurai.  
Study design  
 This is a cross-sectional, cohort study carried out in young MI patients.  
 
Study protocol  
 Patients admitted in Intensive Care Unit of Government Rajaji Hospital, 
Madurai for MI were enrolled in the study.  Patients were interviewed and a designed 
questionnaire was used to collect demographic details, previous history of MI, 
presenting symptoms, the earlier medication and food supplementation used. 
 
Ethical Committee Approval  
 The study protocol was duly approved by the Ethics Committee of 
Government Rajaji Hospital, Madurai.   
 
Collaborating Department  
1. Department of Medicine and Department of Cardiology, Government Rajaji 
Hospital, Madurai. 
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2.  Sai Labs, Madurai. 
 
Study Criteria 
Selection of patients: 
Inclusion Criteria: 
 The following categories of patients from cardiology department are included 
in the study. 
¾ Inpatients admitted for myocardial infarction. 
¾  Patients with age 45 years and below only. 
 
 Exclusion criteria: 
¾ Patients with age above 45 years. 
¾ Patients suffering from diseases such as renal failure, hypothyroidism, 
psoriasis, any malignancies and psychiatric disorders. 
¾ Patients taking drugs such as Methotrexate, oral contraceptive pills, L-
dopa, nicotinic acid and  Theophylline. 
¾ Patients taking folic acid or any vitamin supplement. 
 
 
SOURCE OF DATA 
 Department of Cardiology, Government Rajaji Hospital, Madurai. The data were 
obtained from  
¾ Patient interview 
¾ Treatment chart 
¾ Prescriptions 
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METHOD OF COLLECTION OF DATA  
 This is a cross-sectional, cohort study carried out from June 2006 to Dec 2006, 
to analyze the Homocysteine levels in young MI patients and its association with 
other risk factors. 
 Proforma was prepared as an aid for collecting the demographic data. Model 
of Proforma is given in Appendix. 
 
ESTIMATION OF HOMOCYSTEINE 
 Estimation of Homocysteine was performed by automated immuno assay 
analyzer – IMX ABBOTT System (USA). 
DATA ANALYSIS: 
Graph-Pad software was used for statistical analysis.  
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OBSERVATIONS 
AND RESULTS 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
OBSERVATION AND RESULTS 
 
 The study included 35 cases presenting with MI and 6 healthy subjects as 
controls. 
1. Sex distribution: 
Of the 35 patients with MI, 29 (82.85) were males and 6 (17.14) were females. 
83%
17%
Males
Females
 
 
1.1. Comparison of mean sex and Homocysteine: 
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Sex Mean ± SEM SD 
Male 15.9517 ± 2.167 11.667 
Female 13.866 ±  0.9591 2.347 
 2. BMI: 
 Of the total study population with 35 MI patients, 3 (8.5%) were underweight, 
28 (80%) were normal and 4 (11.42%) were overweight. 
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2.1Comparison of mean BMI 
BMI Mean ±  SEM S.D 
Underweight 17.166± 5.656 9.796 
Normal 15.8928± 2.176 11.481 
Overweight 12.325± 2.185 4.369 
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3. Risk Factors: 
 Of the 35 patients with MI, 22 (62.85%) were smokers, 15 (42.85%) were 
alcoholics, 7 (20%) were Diabetics and 6 (17.14%) were hypertensives. 
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4. Family history of MI:- 
 Of the 35 patients with MI, 7 were having family history of MI and 28 were 
not having any family history of MI. 
80%
20%
No
Yes
 
 
 
 
5. Previous history of MI:- 
 Of the total study population of 35 patients with MI, 14 had previous history 
of MI and 21 did not have. 
40%
60%
Yes
No
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6. Baseline characteristics of study participants  
 
Characteristics Cases Control 
Men 29 (82.85) - 
Diabetes mellitus 7 (20%) - 
Hypertension 6 (17.1%) - 
Current smoking 22 (62.85%) - 
Alcoholics  15 (42.85%) - 
Previous myocardial infarction 14 (40%) - 
Diastolic blood pressure, mm Hg 81.7142± 2.005 78.33± 2.108 
Systolic blood pressure, mm Hg 120.8571± 3.185 122.6± 8.803 
Total cholesterol mg/dL 166.5428± 5.824 111.83± 3.330 
HDL cholesterol, mg/dL 40.628 ±  0.324 45.66 ±  0.321 
LDL cholesterol, mg/dL 81.8571 ±  0.54 93.33 ±  0.431 
VLDL cholesterol, mg/dL 42.3485 ± 1.321 26 ± 1.336 
Triglycerides, mg/dL 200.685 ±  18.741 124.166 ±  4.729 
Serum creatinine 0.9878± 0.3364 0.9714± 0.321 
Blood urea 26.54± 1.464 26.48± 1.324 
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 7. Plasma Homocysteine: 
 Of the 35 MI patients, 8 (22.85%) were having desirable plasma 
Homocysteine levels, 15(42.85%) were having normal but undesirable Homocysteine 
levels, 8 (22.85%) had mild hyperhomocysteinemia, 3(8.5%) were intermediate and 
1(2.5%) had severe hyperhomocysteinemia. 
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7.1. Comparison of mean Homocysteine between group A (case) and group C (control) 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
A 15.5942± 1.801 10.656 
Unpaired t-test    P value = 0.0377 
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 There is a significant difference in Homocysteine levels between case and 
control suggesting an association between Homocysteine and MI in both groups. 
  
8. Association of plasma Homocysteine and other risk factors of MI: 
 The major conventional risk factors of MI are smoking, alcoholism, 
hypercholesterolemia, hypertension and diabetes mellitus.  From the study, it is found 
that of the 35 patients with MI, 22 were smokers, 15 were alcoholics, 7 were diabetics 
6 were hypertensives, 7 had family history of MI and 14 had previous history of MI.  
The new risk factor Homocysteine is associated with the conventional risk factors. 
 
8.1.  Comparison of mean homocysteine of smokers (S1) and Patients without 
smoking (S0) with control group C 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
S1 15.64545±  2.189 10.267 
S0 11.8384 ± 1.046 3.771 
Unpaired t-test  
 
 When Homocysteine levels of group S1 was compared with that of group C, 
the P value was 0.0339 and the result was found to be significant. 
 Comparison of Homocysteine levels of group S0 with group C was shown to 
be not significant with P value of 0.0755. 
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8.2.  Comparison of mean Homocysteine of alcoholics (A1) and without alcohols 
(A0) with group C. 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
A1 17.22166 ±  2.860 11.078 
A0 14.37 ± 2.335 10.444 
 Unpaired t-test 
 Comparison of Homocysteine levels of group A1 with group C showed a 
significant result with P value of 0.261 
 
 When Homocysteine levels of group A0 were compared with that of group C, 
P value was 0.0746 and the result was found to be very not significant. 
 
8.3.  Comparison of mean Homocysteine levels of patients with diabetes mellitus 
(D1) and without diabetes mellitus (D0) 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
D1 11.085 ± 3.812  10.086 
D0 16.73±  2.187 11.572  
Unpaired t-test  
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 When Homocysteine levels of patients with group D1 was compared with 
group C, P value was 0.0042 and the result was found be very significant. 
 Comparison of mean Homocysteine value of group D0 with group C gave a P 
value 0.0367 and result was considered to be significant 
8.4.  Comparison of plasma Homocysteine levels of patients with hypertension 
(H1) and without hypertension (H0) with controls 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
H1 12.35± 1.358  3.327 
H0 16.2656 ±  2.143  11.541  
Unpaired t-test  
 Comparison of mean Homocysteine levels of patients with group H1 with 
group C was considered to be very significant with P value of 0.0012. 
 Comparison of mean Homocysteine levels of group H0 with group C was 
considered to be very significant with P value of 0.0445. 
 
8.5.  Comparison of mean Homocysteine of patients without family history of MI 
(FH0) and with family history MI (FH1) with group C. 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333±  0.2765 0.6772 
FHO 15.2214 ± 2.067 10.939 
FH1 17.0857±  3.812 10.086 
Unpaired t-test 
 When Homocysteine levels of FHO was compared with group C, the result was 
found to be not quite significant with P value of 0.0530. 
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 Comparison of Homocysteine levels of FH1 with group C was found to be 
significant with P value of 0.0231  
 
 
8.6.  Comparison of mean Homocysteine of patients without previous history of 
MI (PHO) and with previous history of MI (PH1) with group C 
 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333 ±  0.2765 0.6772 
PHO 15.4333 ± 2.177 9.978 
PH1 11.987± 3.209 11.987 
Unpaired t-test 
 When Homocysteine levels of PHO was compared with group C, the P value 
was < 0.001 and the result was extremely significant. 
 
 When Homocysteine levels of PH1 were compared with group C, the result 
was not quite significant with P value of 0.668. 
 
8.7. Comparison of mean Homocysteine of patients with (T1) and without 
hypercholesterolemia (T0) and group C 
Group Mean Homocysteine  ± SEM S.D 
C 6.1333 ±  0.2765 0.6772 
T1 14.7217±  1.878 9.007 
T0 17.466 ± 3.873 13.417 
Unpaired t-test 
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 Comparison of Homocysteine levels of group T1 with group C was found to 
be significant with the P value of 0.0292. 
 Comparison of Homocysteine levels of group T0 with group C gave P value 
0.0621 and was considered to be not quite significant. 
 
 
 
9. Effects of risk factors on Homocysteine 
 
Group Risk factors Number Hcy mean ±  
SEM 
 
A 
 
CAD alone (C0) 
 
2 
 
15.585 ±  6.355 
 
B. CAD + any one risk factor 
(HTN / 
DM/SMOKING/HYPERCHOLESTEROLAEMIA
/ ALCOHOLISM) (C1) 
7 15.585 ±  6.355 
C. CAD + any two risk factors (C2) 89 17.566± 4.307 
D. CAD + any three risk factors (C3) 8 16.3375± 3.377 
E. CAD + any four risk factors (C4) 5 15.44± 0.98111 
F. CAD + all five risk factors (C5) 54 11.3± 1.85 
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 9.1. Students - Newmann-Keuls Multiple comparison test: 
 
 
 
Comparison Mean P value 
C5 Vs C2 -6.267 ns p > 0.05 
C5 Vs C3 -5.030 ns p > 0.05 
C5 Vs C1 -4.286 ns p > 0.05 
C5 Vs C4 -4.140 ns p > 0.05 
C5 Vs C0 -1.450 ns p > 0.05 
C0 Vs C2 -4.817 ns p > 0.05 
C0 Vs C3 -3.588 ns p > 0.05 
C0 Vs C1 -2.836 ns p > 0.05 
C0 Vs C4 -2.690 ns p > 0.05 
C4 Vs C2 -2.127 ns p > 0.05 
C4 Vs C3 -0.8975 ns p > 0.05 
C4 Vs C1 -0.1457 ns p > 0.05 
C1 Vs C2 -1.981 ns p > 0.05 
C1 Vs C3 -0.7518 ns p > 0.05 
C3 Vs C2 -1.229 ns p > 0.05 
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10. Comparison of mean BMI of control and patients 
Group Mean BMI  ± SEM S.D 
Control BMI 21.90725±  0.4430 1.085 
Patient BMI 22.14668 ± 0.4832 2.740 
 
 Comparison of BMI of case and control was found to be not significant with P 
value 0.8352. 
 
11. Comparison of  total cholesterol and triglycerides of case and control  
Group Mean ±  SEM S.D P value 
1. Total cholesterol 
Control 
Case 
 
157.64±  6.753 
166.54 ±  5.824 
 
 
16.54 
34.452 
 
 
0.5130 
 
 
1. Triglycerides 
Control 
Case 
 
134..333 ± 3.490 
200.6857 ± 18.741 
 
 
8.548 
110.87 
 
 
0.1551 
Unpaired t-test  
 Comparison of total cholesterol and triglycerides of control and case was not 
found to be significant. 
 
 
 
 
 
50 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     DISCUSSION    
 
Prevalence of risk factors is higher and rapidly raising in Indian population. 
This predisposition to accelerated atherosclerosis seems to have genetic predisposition 
but is being enhanced by changing lifestyle, dietary and cultural preferences, and 
suboptimal application of health care.  The activation of “thrifty” gene is associated 
with the development of obesity and metabolic syndrome. Even though the 
environmental and behavioral responses to urbanization and westernization appear to 
be consistent across cultures, the genetically determined metabolic response to these 
environmental changes and resulting CAD risk profiles may vary in different ethnic 
groups.55  Ethnicity is a strong surrogate for gene-environment interactions and it may 
underlie the tendency to develop obesity and atherosclerosis due to selection of the 
“thrifty gene”, that increases efficiency of fat storage.  The extent to which these 
variations in different ethnic groups are due to genetic or environmental factors 
remains unclear.56 
 
 According to the Indian studies, the prevalence rate of CAD was 9.7% in 
Delhi, 3.5% in Rajasthan and 11% in urban population of South India.46 
 
 Among all the ethnic groups studied, the standard mortality ratio for men born 
in the Indian subcontinent and aged between 20 and 69 years was by far the highest.47 
 
 In the analysis by Balarajan, the excess mortality seen among immigrants from 
the subcontinent steadily increased with decreasing age.  Men in the age group 20-29  
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and 30-39 years had SMRs of 313 and 210, respectively.  The rate of first MI was five 
times higher among Indian men compared to the Europeans in the study.48  
Further, the mean age at first MI was about 5 years lower for the Indian men 
(50.2 v 55.5 years). Indians also suffered larger infarcts as estimated from peak 
creatine kinase (CK) levels and degree of left ventricular dysfunction.  Lowry et al., 
found a small increase in the atheroma score among South Asian patients when 
compared to the Europeans in the study.  More South Asian patients (38% v. 22%) 
were found unsuitable for surgery because of extensive disease.  CAD tends to occur 
earlier in life among people of Indian descent.49 
 
 In addition to the conventional risk factors such as smoking, HT, DM, 
hypercholesterolemia, obesity and reduced physical activity Hyperhomocysteinemia 
was  found to be independent risk factor of CAD. 
 
 Identification of new markers such as homocysteine associated with an 
increased risk of CAD may provide a better insight into the pathology of coronary 
atherosclerosis and facilitate the development of preventive and therapeutic measures.   
 
 Normal values of plasma total homocysteine are between 5 and 15 µ mol/L.  
In our study, the mean plasma homocysteine in healthy subjects was 6.133 ± 0.2765 
and in CAD patients, the total plasma homocysteine was 15.5942± 1.801 (P = 0.0377) 
indicating that homocysteine level is an independent marker of CAD.  A two fold 
increase in likelihood of MI among persons with a total Hcy concentration more than 
or equal to 15 µ mol/L has been noted in an United States study.50 
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An Indian study which gave a mean value of 22.81 ±  13.9 in cases and 7.77 ±  7.3 in 
controls showed a significant difference of homocysteine values between the two 
groups and  hence showed  increased homocysteine levels among patients with 
coronary artery disease.44  
 
 However, another Indian study with a mean homocysteine value of four cases 
as 18.30 ± 10.08 µ mol/L and control 18.04 ± 10.65 reported a negative association 
between homocysteine with MI.23 
 
Homocysteine and Smoking: 
 CAD patients who were smokers had a mean Hcy level of 15.65 ± 2.189 as 
compared to 11.84 ± 1.046 in CAD patients who are non-smokers.  This higher level 
of Hcy may be due to the influence of smoking in homocysteine metabolism. Among 
secondary causes of hyperhomocysteinemia, smoking plays an important role by 
interfering with the synthesis of pyridoxal phosphate, which is important for the 
conversion of homocysteine to cystathione by the enzyme cystathione b synthase.51 
 
Homocysteine and alcoholism: 
 Alcoholic intake increases the absorption of vitamins and interferes with the 
metabolism of homocysteine, leading to hyperhomocysteinemia. In our study mean 
Hcy of alcoholics was found to be 17.22 ± 2.86 as compared to 14.37 ± 2.335 in non-
alcoholics. 
 
Homocysteine and Hypertension: 
 A number of studies have shown a correlation between hyperhomocysteinemia 
and HT.   
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This was confirmed in our study too, where; mean Hcy value of 16.26 in 
hypertensives and 12.35 in non hypertensives.  However, a contradictory report was 
obtained from a western study with a mean value of tHcy 10.4 ± 53 in 
hypertensives.29 
 
 
 
Homocysteine and Diabetes Mellitus: 
 Varied results were observed among diabetes as well. Munshi et al. 
demonstrated elevated homocysteine levels in non-insulin dependent diabetes subjects 
compared to age matched controls52 and Hoffman et al, reported that 
hyperhomocysteinemia is more common in type 1 diabetic patients with 
nephropathy.53  Deepa et al. did not reveal any significant increase in homocysteine 
level in diabetes with CAD.54 In our study population, there was a small difference in 
Hcy levels among diabetes and non diabetes patients (17.085 and 16.72).   
 
Homocystiene and hypercholesterolaemia  
 In the Hordaland study in Norway, increasing plasma levels of cholesterol, 
triglycerides and smoking were associated with increasing levels of homocysteine.  In 
our study, homocysteine levels were actually less (14.721) in CAD patients with 
hypercholesterolemia when compared to CAD patients (17.45) without this risk 
factor.  Lowered Hcy may be due to change in life style adopted by patients as part of 
treatment for high cholesterol.  In addition majority of our patients were manual 
workers, not having sedentary life style pattern. 
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HDL was comparatively less in patients (40.6) as compared to controls (45.66).  
VLDL was relatively high in patients (42.3) as compared to controls.  These results 
help to confirm the fact that hyperhomocysteinemia along with conventional risk 
factors give rise to CAD and MI in young individuals.  Alarmingly, out of 35 patients 
studied (65.7%) 23.5 had hypercholesterolemia. 
Homocysteine and Stroke: 
 Hyperhomocysteinemia is an independent risk factor for ischemic strokes in 
young Asian adults.  The relationship between increasing Hcy and stroke is strong and 
significant. The association with large-artery strokes suggests that 
hyperhomocysteinemia may increase stroke risk via a proatherogenic effect. The 
burden of stroke arises largely from the elderly population.  However, there remains a 
small but significant subset of younger patients with ischemic stroke, in whom 
conventional vascular risk factors play a smaller role.45 
 
 Homocysteine is believed to cause atherogenesis and thrombogenesis via 
endothelial damage, vascular smooth muscle proliferation and coagulation 
abnormalities.  High Hcy levels are associated with increased risk of cardiovascular 
and cerebrovascular diseases.35  Our study findings are consistent with these reports : 
CAD patients with stroke showed a very high homocysteine value 53µ mol/litre 
compared to other CAD patients without such complications. 
 
 Hcy is postulated to cause ischemic stroke via various mechanisms.  It may 
promote atherogenesis by damaging the vascular matrix, increasing oxidative injury 
to arterial endothelium and enhancing proliferation of vascular smooth muscle.  High 
levels of Hcy have been associated with extra-cranial carotid disease.  It may also be  
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prothrombotic and impair vasomotor regulation Hcy is thus a biologically plausible 
factor in the pathogenesis of ischemic stroke, in particular large-artery strokes.  Total 
Hcy concentration is a strong predictor for incident ischemic stroke among patients at 
increased risk because of CAD.  The graded association observed is independent of 
traditional risk factors in inflammatory markers and indicates the importance of 
homocysteine levels in patients with preexisting vascular diseases.45 In the present 
study; we provide evidence consistent with a strong graded association 
between total homocysteine concentration and incident ischemic stroke in 
patients with preexisting atherosclerotic vascular disease 
 
Homocysteine and Obesity: 
 None of the patients in our study were found to be obese, 8.5% were 
underweight with a Hcy value (17.166), 80% normal body weight with Hcy value 
(15.8928) and 11.42% over weight patients with 12.325 Hcy.  Elevated levels of Hcy 
in underweight subjects could be due to malnutrition and its impaired effect on Hcy 
metabolism. 
 
Homocysteine and family history of CAD: 
 It is also interesting to note that Hcy levels were higher (17.08) in patients 
with a family history of MI in comparison of patients without such risk factor (Mean 
Hcy 15.22). 
 
Homocysteine and previous history of CAD: 
 Many studies have shown that patients with MI had significantly elevated 
tHcy levels compared to patients without such history as well as to controls.32, 24 
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     However, in our study it was  found that tHcy of patients with previous history was 
lower that of patients with previous history of MI (11.987 ± 3.20 Vs 15.43 ±  2.17). 
 This may be due to the effects of administration of lipid lowering agents 
following the previous MI events.  It has been reported in a study that lower levels of 
tHcy were observed amongst patients taking lipid-lowering agents.21 
 
 
Homocysteine and gender: 
 In this study, no significant difference was found in the total homocysteine 
levels of men (15.95 ± 2.167) and women (13.8 ± 0.9291). 
 
 The  study matched with an Indian study where large number of women had 
high total homocysteine and were deficit in vitamin B12.33 
 
 Hyperhomocysteinemia as a risk factor for MI may have profound public 
health implications because total homocysteine can be lowered inexpensively and 
easily by modification of dietary patterns and vitamin supplements.  But a Western 
study had shown that vitamins did not reduce the risk of major cardiovascular events 
in patients with vascular disease.38 
 
 The results of ongoing clinical trials to determine the effect of multivitamin 
therapy on CAD are awaited.  If casually related, our findings suggest that young 
people with high risk of MI may particularly benefit from interventions that lower 
total homocysteine concentrations.   
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CONCLUSION 
 
 
 
 
 
 
 
 
   CONCLUSION 
 
 
At the threshold of this millennium, CAD is looming large as the new 
epidemic afflicting Indians at a relatively younger age. Of the 35 MI patients, 
8(22.85%) were having desirable plasma homocysteine levels (<10µmol/L), 
15(42.85%) were having normal but undesirable homocysteine levels (10-
15µmol/L), 8(22.85%) had mild hyperhomocysteinemia (15-20µmol/L), 
3(8.5%) were intermediate (20-50 µmol/L) and 1 (2.5%) had severe 
hyperhomocysteinemia (>50%).   
In the study, homocysteine was identified as a nontraditional risk 
factor for MI. Among the study population of MI it was found that 77.14% 
had higher homocysteine than control.  In the study, the mean plasma 
homocysteine level in healthy subjects was 6.13±0.28µmol/l and in CAD 
patients the total plasma homocysteine was 15.6±1.8µmol/l(P=0.0377) 
indicating that homocysteine level is an independent marker of CAD.  
It was also found that homocysteine levels were higher in patients who 
had additional conventional risk factors when compared to patients without 
such risk factors except hypercholesterolemia.   
However, as the study was limited to a small population due to 
financial constraint, analysis of a larger group would definitely give an insight 
into the various causative factors leading to hyperhomocysteinemia and its 
role in CAD amongst the young Indian population.  
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 As such Asian Indians are genetically predisposed to CAD.  Hence it is 
mandatory to determine homocysteine levels in people after thirties so that preventive 
measures such as vitamin supplementation and life style modifications could be 
undertaken and thus reduce the incidence and mortality due to CAD.. 
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PROFORMA 
Name of the patient : 
Age    :   Sex: 
Marital Status  :   
Body Weight (in kg) :   Height (in cms.): 
BMI    : 
Food habits   : Veg:  Non-veg:  
If non-veg, how frequently? 
 
 
SYMPTOMS: 
• Giddiness 
• Palpitation 
• Chest discomfort 
• Headache 
  
Habits : a. Smoker   
  If yes, how long?   : 
  Number of cigarettes/day  : 
  If discontinued, whether after MI: 
  b. Alcoholic 
  If yes, how long?   : 
  Frequency (mild/moderate) : 
  If discontinued, whether after MI: 
  
Concomitant disease: 
 
  Kidney failure   : 
  Psoriasis    : 
  Hypothyroidism   : 
  Diabetes Mellitus   : 
  Hypertension   : 
  CAD     : 
 
 
FAMILY HISTORY: 
 Diabetes mellitus : 
 CAD          : 
 HYPERTENSION : 
 CKD                         : 
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Drug history 
  a. Oral contraceptive  pills : 
  b. L-Dopa    : 
  c. Methotrexate   : 
  d. Nicotinic acid   : 
  e. Theophilline   : 
  f. Exposure to nitrous oxide : 
Any folic acid / vitamin being taken   : 
General examination: 
 Pallor 
 Jaundice 
 Pedal edema 
 External markers of hyperlipidemia 
 PR: 
 BP: 
Systemic examination: 
 CVS : 
 RS : 
 ABDOMEN: 
 CNS : 
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Diagnosis      : 
Investigation: 
  Haemoglobin%   : 
  ESR     : 
  Blood sugar    : 
  Serum creatinine   : 
  Serum urea    : 
  Lipid profile    : 
  i. Total Cholesterol   : 
  ii. Triglycerides   : 
  iii. HDL    : 
  iv. VLDL    : 
  v. LDL    : 
  ECG 
  ECHO    : 
PLASMA HOMOCYSTEINE    : 
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MASTER CHART 
CASES 
S.No. Age Sex Smoking Alcohol FH PH HT DM BMI TC HDL LDL TGL HOMOC
1 32 M N Y N N N N 23.6 149 40 87 110 12 
2 40 M Y Y N Y N N 19.6 181 49 102 151 14.2 
3 43 M N N N N N N 22 140 42 75 114 12.8 
4 43 F N N N Y N Y 24.1 184 42 105 185 12.7 
5 40 F N N Y N Y N 28.1 189 40 111 192 16.2 
6 40 M Y N Y Y N N 23.7 226 40 138 238 16 
7 44 M N N N N N N 23.5 201 40 125 180 18.2 
8 42 M Y Y N N Y N 23.6 180 42 125 130 10 
9 35 M Y N N Y Y N 28.1 183 40 130 128 12.4 
10 30 M Y Y N N N N 18.3 155 42 72 203 14.2 
11 42 M Y N N Y N Y 20.3 184 40 92 278 16.2 
12 40 M Y N N N N N 18.1 207 40 151 78 28.4 
13 45 F N N N Y N Y 23.4 147 46 74 179 14.5 
14 45 F N N N Y N N 20.8 209 38 78 230 09.8 
15 45 M N N N N N N 23.8 152 38 90 120 12.7 
16 45 F N N N N Y Y 21.4 181 40 103 191 14.2 
17 31 M Y Y N N N N 23.4 181 42 104 174 29 
18 42 M N N N Y N N 21.5 204 40 110 260 7.8 
19 45 M N N N N N Y 21.9 146 44 83 106 5.9 
20 39 M Y N Y N N N 17 143 40 68 176 10.4 
21 39 M Y Y N Y Y N 23.9 214 42 136 220 6.2 
22 28 M Y Y N N N N 19.5 138 42 68 161 16.9 
23 42 M Y Y N N N Y 27.6 202 40 130 108 19.2 
24 26 F N N N Y N N 24.4 188 38 128 110 15.8 
25 45 M Y Y N Y Y Y 22.4 211 40 130 207 7.6 
26 44 M N N Y N N N 24.6 217 40 130 239 16.2 
27 37 M Y Y N N N N 26.6 132 42 71 97 10.3 
28 42 M Y N Y N N N 21.5 252 40 170 199 12.3 
29 31 M Y N Y Y N N 24.5 188 40 110 193 16 
30 41 M Y Y N N N N 21.6 200 36 130 180 11 
31 35 M Y Y N N N N 21 137 42 79 80 38 
32 37 M Y Y Y Y N N 23.4 194 42 124 120 52.8 
33 36 M Y N N N N N 23 216 40 140 114 6.8 
34 42 M Y Y N Y N N 22 134 40 73 105 12.7 
35 45 M Y Y N N N N 23.4 124 40 64 133 6.8 
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CONTROLS 
 
 
 
 
S.No. Age Sex Smoking Alcohol FH PH HT DM BMI TC HDL  LDL TG HOMOC
1 32 M Y N N N N N 21 126 42 65 126 6.8 
2 30 F N N N N N N 20 130 38 70 150 5.6 
3 40 F N N N N N N 19 154 40 90 119 6.7 
4 35 M N Y N N N N 22 132 44 70 105 5.8 
5 38 F N N N N N N 23 149 40 75 128 9 
6 35 F N N N N N N 23 130 38 75 118 6 
 
HT – HYPERTENSION   HDL – HIGH DENSITY LIPOPROTEINS 
DM- DIABETES MELLITUS   LDL- LOW DENSITY LIPOPROTEINS 
BMI- BODY MASS INDEX   TG-TRIGLYCERIDES 
TC- TOTAL CHOLESTROL   HOMOC-HOMOCYSTEINE 
PH – PAST HISTORY OF IHD  FH- FAMILY HISTORY OF IHD 
 
